Key Questions Answered

• What are the changes in the healthcare landscape that are necessitating a change in the pharma business model?
• What types of partnerships will be most critical for success in the new commercial approaches?
•  In what ways are tech firms posing competition to pharma companies?
• Which therapeutic areas are most impacted by greater use of digital tools?
• What lessons can pharma take from other sectors’ adaptions to technological change?
• What challenges must pharma overcome to remain competitive in tomorrow’s marketplace?

Report Highlights

1. As real-time, high-volume data become increasingly central both to delivering and developing effective therapies, pharmaceutical firms are up against tech titans including Amazon, Apple, and Google, as the latter shift their attention to the highvalue healthcare space.
2. Pharmaceutical companies have been slow to acknowledge the threat of technology players in healthcare, with many citing regulatory hurdles as their main defense. But this argument is weakening, as regulators themselves adjust to the digital age, and as tech giants hire and build the expertise they need to address regulations.
3. A key benefit of working with digital health players is that they are cozying up to providers with an attractive proposition: user-friendly, socially acceptable tools that may improve outcomes by themselves or through increasing the efficiency of traditional drugs, without the complications of supply chains or pharmacological side effects.
4. Most pharmaceutical firms know that shifting their businesses to embrace digital, consumer-centricity; value-based and crosssectoral partnerships; and the universe of value that lies beyond novel biopharmaceuticals will not bring immediate financial returns.
5. Change – including cultural change – can cost money in the short term. But, ultimately, the returns will follow.